Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
Algernon Pharmaceuticals has entered an Investigator-Initiated Clinical Trial Agreement with Yale University to investigate multiple intravenous doses of DMT for the treatment of depression.
The first patient has now been dosed in IntelGEnx and atai Life Sciences’ Phase 1 clinical trial to investigate buccal VLS-01 – a buccal film containing...
Researchers from Inserm, CNRS, Sorbonne University and clinicians from the AP-HP and at Paris Brain Institute identified one of the mechanisms explaining ketamine effect as an...
Chief clinical development officer of HMNC Brain Health, Hans Eriksson, speaks to Psychedelic Health about how the company’s formula, ‘Ketabon’, will provide the therapeutic benefits of ketamine without...
A team of scientists has developed LSD-like compounds that fit into the 5HT2a receptor – the main target of substances such as LSD and psilocybin.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
Small Pharma has completed enrollment in its Phase 2a clinical trial of its intravenous formulation of DMT – candidate SPL026 – with psychotherapy for the treatment...
Cybin has now dosed the first patients in its Phase 1/2a trial clinical trial investigating in psilocybin analogue CYB003 for the treatment of major depressive disorder...
New study findings have shown that mice respond more to the antidepressant effects of the drug ketamine when administered by men and not by women.
